Salek-Ardakani et al., 2006 - Google Patents
OX40: OX40L axis: emerging targets for immunotherapy of human diseaseSalek-Ardakani et al., 2006
View PDF- Document ID
- 9125773887057286591
- Author
- Salek-Ardakani S
- Song A
- Humphreys I
- Croft M
- Publication year
- Publication venue
- Current Immunology Reviews
External Links
Snippet
Recent advances in our understanding of the mechanisms through which T cells are activated have led to new therapeutic approaches in the treatment of immunological disorders. An emerging target for selective immune intervention has been the manipulation …
- 101710040448 TNFRSF4 0 title abstract description 172
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sugamura et al. | Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40 | |
| AU2018203924B2 (en) | Toxicity management for anti-tumor activity of cars | |
| Nolte et al. | Timing and tuning of CD27–CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology | |
| Watts | TNF/TNFR family members in costimulation of T cell responses | |
| Mackey et al. | The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells | |
| Barrett et al. | New developments in allotransplant immunology | |
| Raimondi et al. | Naturally occurring regulatory T cells: recent insights in health and disease | |
| WO2008138017A2 (en) | Methods and compositions for modifying t cell immune responses and inflammation | |
| Kwon et al. | 4-1BB: still in the midst of darkness | |
| US20210268023A1 (en) | Enhanced CAR Tregs and Bi-Specific Antibodies for Induction of Immune Tolerance, Treating Autoimmune Diseases and Preventing Transplantation Rejection | |
| US20250262243A1 (en) | Bispecific chimeric antigen receptors targeting cd20 and bcma | |
| WO2024215708A2 (en) | Bispecific chimeric antigen receptors targeting bcma and cd19 | |
| Vinay et al. | TNF superfamily: costimulation and clinical applications | |
| JP2025083396A (en) | Chimeric antigen receptors for treating myeloid malignancies | |
| Hori | Roles of OX40 in the pathogenesis and the control of diseases | |
| US20230321239A1 (en) | Chimeric antigen receptor t cells for treating autoimmunity | |
| JP2008518882A (en) | Anti-4-1BB antibody-containing drug composition for treating or preventing rheumatoid arthritis | |
| Salek-Ardakani et al. | OX40: OX40L axis: emerging targets for immunotherapy of human disease | |
| JP7701908B2 (en) | Regulatory T cells expressing anti-CD38 chimeric antigen receptors | |
| Chiffoleau et al. | Apoptosis and transplantation tolerance | |
| Choi | New Therapeutic Challenges | |
| Ferrera et al. | New therapies in SLE | |
| WOOD et al. | 21 Approaches to | |
| Spriewald et al. | Cytokines as mediators in immunologic tolerance | |
| Smolen et al. | Contemporary targeted therapies in rheumatology |